| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 01/30/2003 | WO2003007689A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c |
| 01/30/2003 | WO2002070510A3 Amino dicarboxylic acid derivatives with pharmaceutical properties |
| 01/30/2003 | WO2002064160A8 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 01/30/2003 | WO2002057271A3 Thienopyrimidine-based inhibitors of the src family |
| 01/30/2003 | WO2002055136A3 Intrasvascular drug delivery device and use therefor |
| 01/30/2003 | WO2002048180A3 Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament |
| 01/30/2003 | WO2002018375A1 Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof |
| 01/30/2003 | WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides |
| 01/30/2003 | WO2001090359A3 G-protein coupled receptors |
| 01/30/2003 | US20030023098 Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| 01/30/2003 | US20030023086 For therapy of thrombosis in humans and other mammals |
| 01/30/2003 | US20030023079 For therapy of thrombosis in a mammal |
| 01/30/2003 | US20030023048 Chemical modification of proteins to improve biocompatibility and bioactivity |
| 01/30/2003 | US20030022939 4-Fluoro-N- indan-2-yl benzamide and its use as a pharmaceutical |
| 01/30/2003 | US20030022935 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents |
| 01/30/2003 | US20030022925 5-(dialkylamine)alkoxy)-1H-pyrazole derivatives |
| 01/30/2003 | US20030022916 Anticoagulants |
| 01/30/2003 | US20030022909 Use of methylnaltrexone to treat immune suppression |
| 01/30/2003 | US20030022893 Hydroxamic and carboxylic acid derivatives |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022883 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 01/30/2003 | US20030022865 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 01/30/2003 | US20030022850 Isolated nucleic acid molecule that hybridizes under stringent conditions or shares 80% sequence identity with a defined genomic region upstream of coding region of G-CSF gene, and DNA construct containing that DNA molecule as target |
| 01/30/2003 | US20030022836 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| 01/30/2003 | US20030022354 Protein c derivatives |
| 01/30/2003 | US20030022303 Expression vector for use in the treatment of blood disorders |
| 01/30/2003 | US20030022185 Secreted protein HLHFP03 |
| 01/30/2003 | US20030021785 Use of rank antagonists to treat cancer |
| 01/30/2003 | US20030021773 Arginine mimetics as factor Xa inhibitors |
| 01/30/2003 | US20030021769 Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer |
| 01/30/2003 | CA2454545A1 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]naphthalenyl derivatives with antipsychotic activity |
| 01/30/2003 | CA2454418A1 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | CA2454043A1 Use of magnesium for preventing in-stent thrombosis and complications after arterial angioplasty with stent placement |
| 01/30/2003 | CA2453986A1 Glycoprotein vi fusion proteins |
| 01/30/2003 | CA2453650A1 Substituted isoindoles and the use thereof |
| 01/30/2003 | CA2453636A1 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | CA2453613A1 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 01/30/2003 | CA2453602A1 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2452677A1 Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides |
| 01/30/2003 | CA2452322A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | CA2451445A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 01/30/2003 | CA2451392A1 Prostaglandin analogues as ep4 receptor agonists |
| 01/30/2003 | CA2450437A1 1-phenylsulphonyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application |
| 01/30/2003 | CA2417955A1 Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 01/29/2003 | EP1279674A2 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| 01/29/2003 | EP1279666A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/29/2003 | EP1278893A2 Diagnosis of diseases associated with dna replication |
| 01/29/2003 | EP1278869A2 Proteases |
| 01/29/2003 | EP1278849A2 Thrombopoietin receptor modulating peptide |
| 01/29/2003 | EP1278846A2 Cytoskeleton-associated proteins |
| 01/29/2003 | EP1278843A2 Rna metabolism proteins |
| 01/29/2003 | EP1278838A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 01/29/2003 | EP1278826A1 Novel proteins |
| 01/29/2003 | EP1278778A2 Modified peptides, comprising an fc domain, as therapeutic agents |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278750A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives |
| 01/29/2003 | EP1278749A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 01/29/2003 | EP1278748A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 01/29/2003 | EP1278744A1 Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors |
| 01/29/2003 | EP1278734A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
| 01/29/2003 | EP1278729A1 Benzosuberonylpiperidine compounds as analgesics |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278540A2 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 01/29/2003 | EP1278533A2 Use of echinacea as a hematinic agent |
| 01/29/2003 | EP1278532A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses |
| 01/29/2003 | EP1278502A2 Protease inhibitors |
| 01/29/2003 | EP1102761B1 Cyclopentabenzofuran derivatives and their use |
| 01/29/2003 | EP1030836B1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 01/29/2003 | EP0910573B1 New amino acid derivatives and their use as thrombin inhibitors |
| 01/29/2003 | EP0817772B1 Pyrrolidinyl hydroxamic acid compounds and their production process |
| 01/29/2003 | CN1394201A Substituted glutarimides and use thereof IL-12 production inhibitors |
| 01/29/2003 | CN1393241A Onion extract and its preparing process |
| 01/29/2003 | CN1099871C Shuanggan injecta and preparing method thereof |
| 01/28/2003 | US6511997 For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease |
| 01/28/2003 | US6511973 Enzyme inhibitors of blood coaggulation factor X for use as anticoaggulants in the treatment of cardiovascular diseases associated with thromboses |
| 01/28/2003 | CA2284910C Pharmaceutical combined preparations containing erythropoietin and iron preparations |
| 01/28/2003 | CA2127553C Peptides with organo-protective activity, process for their preparation and their use in the therapy |
| 01/27/2003 | WO2002010127A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/27/2003 | CA2417427A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/24/2003 | WO2002010145A1 Urethane derivatives |
| 01/24/2003 | CA2417268A1 Urethane derivatives |
| 01/24/2003 | CA2394209A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006670A2 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors |
| 01/23/2003 | WO2003006612A2 Production of transduced hematopoietic progenitor cells |
| 01/23/2003 | WO2003006477A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 01/23/2003 | WO2003006452A1 New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 01/23/2003 | WO2003006427A1 Compounds that release nitric oxide at controlled rates upon photolysis |
| 01/23/2003 | WO2003006070A2 Improved chelator conjugates |
| 01/23/2003 | WO2003006054A1 Pharmaceutically stable hemostatic compositions |
| 01/23/2003 | WO2003006042A1 Peptide for regulation of tissue plasminogen activator |
| 01/23/2003 | WO2003006011A1 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors |
| 01/23/2003 | WO2003005999A2 Methods of treating cytokine mediated diseases |
| 01/23/2003 | WO2003005819A1 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent |
| 01/23/2003 | WO2002076475A3 Glycosaminoglycan anticoagulants derived from fish |
| 01/23/2003 | WO2002066475A3 Tricyclic androgen receptor modulator compounds |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002049413A3 Thrombopoietin mimetics |